HIV

Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead’s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (...

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods...

Tuesday, GSK Plc (NYSE:GSK) / Pfizer Inc (NYSE:PFE)-owned ViiV Healthcare said its two-drug HIV regimen Dovato was as effective as Gilead Science Inc‘s (NASDAQ:GILD) three-drug combo Biktarvy in a head-to-head trial. Japanese pharmaceutical company Shionogi & Company is also a...

The Biden administration is working to preserve a crucial federal mandate compelling health insurers to cover preventive care services, including HIV-preventing medication and cancer screenings, without additional costs to patients.  This mandate is integral to the 2010 Affordable Care Act (ACA)....

In a recent tweet, tech mogul Bill Gates reflected on the significant impact made by Nelson Mandela in the fight against apartheid and HIV/AIDS. What Happened: Gates expressed admiration for the African leader’s contributions to society with the tweet: “Today, I’m reflecting on...

Blockchain-powered health care ecosystem Immunify.Life on Friday announced it has raised $2 million from venture capitalists in the blockchain and digital transformation spaces as part of its seed and private investment rounds. The company's valuation after the fundraise is unclear. The...

Many of those who live with HIV and Acquired Immunodeficiency Syndrome (AIDS) are aware of how cannabis can help reduce certain symptoms like headaches and nausea. While we live in a world where HIV is no longer a death sentence, research on the connection between cannabis and HIV is growing...

The FDA has approved ViiV Healthcare's Cabenuva (cabotegravir, rilpivirine) for HIV-1 in virologically suppressed adolescents. The approval covers patients aged 12 years or older and weighing at least 35kg on a stable antiretroviral regimen, with no history of treatment failure...

Gilead Sciences Inc (NASDAQ: GILD) announced new one-year results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir in heavily pretreated multi-drug resistant HIV patients. The findings demonstrated that lenacapavir, administered every six months in combination with...

A woman in the New York City area appears to have been cured of an HIV infection, Wall Street Journal reported, providing a roadmap that could help researchers who are developing gene therapies to cure HIV. According to the woman's doctor, there were no detectable signs of the human...

IAVI, the nonprofit scientific research organization, and Moderna Inc (NASDAQ: MRNA) have administered the first doses of experimental HIV vaccine antigens in a clinical trial.  The Phase 1 trial, IAVI G002, is designed to test the hypothesis that sequential administration...

Apple Inc (NASDAQ: AAPL) said it would donate half the proceeds arising out of the sales of its (PRODUCT) RED sales to Global Fund for the fight against COVID-19 in sub-Saharan Africa. What Happened: The Tim Cook-led company released a video on Wednesday that showcased a series of (RED) products...

The FDA has approved ViiV Healthcare's Apretude, the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option, to reduce the risk of sexually acquired HIV-1.  The long-acting injectable was approved for use in adults and adolescents weighing at least 35...

After the external data monitoring committee's recommendation, Merck & Co Inc (NYSE: MRK) has paused in enrollment for the IMPOWER 22 (MK-8591-022) and IMPOWER 24 (MK-8591-024) Phase 3 studies evaluating islatravir (ISL) for pre-exposure prophylaxis (PrEP) in people at...

Merck & Co Inc (NYSE: MRK) announced an update regarding the Phase 2 IMAGINE-DR trial (MK-8507-13), evaluating the combination of MK-8507 and islatravir (ISL) as a once-weekly oral treatment for HIV-1 infection.  Decreases in total lymphocyte and CD4+ T-cell counts were...